Area: Evidence > Guidelines
NICE has published guidance (Technology Appraisal Guidance 237) recommending against the use of ranibizumab within the NHS for the treatment of visual impairment due to diabetic macular oedema. Those who are currently receiving this treatment should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
The full guidance (please see link below) discusses the evidence considered by the Appraisal Committee. This notes that the manufacturer's model resulted in an incremental cost effectiveness ratio (ICER) of ranibizumab (Read more...)